Literature DB >> 8494998

Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia.

Y Yoshida1, J Stephenson, G J Mufti.   

Abstract

The myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic disorders predominantly affecting the elderly. Patients frequently develop acute leukemia, but the majority suffer from the consequences of bone marrow failure. The underlying acquired genetic abnormality is the inadequate production of dysplastic and poorly functional cells resulting from defective differentiation and premature cell death of the abnormal hematopoietic clone. Although the pathogenesis is unknown, recent evidence suggests that a sequence of DNA lesions leads to alteration of the cellular function, emergence and consequent evolution of the premalignant clone.

Entities:  

Mesh:

Year:  1993        PMID: 8494998

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  7 in total

1.  Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes.

Authors:  D Marisavljević; Z Rolović; D Sefer; N Basara; D Ilić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  Behcet's disease complicated with myelodysplastic syndrome: a report of two cases and review of the literature.

Authors:  K Yano; K Eguchi; K Migita; H Takashima; M Tamura; K Izumino; I Sasagawa; N Sadamori; S Nagataki
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

Review 3.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response.

Authors:  Takayuki Ishikawa; Kaoru Tohyama; Shinji Nakao; Yataro Yoshida; Masanao Teramura; Toshiko Motoji; Masaaki Takatoku; Mineo Kurokawa; Kinuko Mitani; Takashi Uchiyama; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

5.  Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.

Authors:  Y Yoshida; N Anzai; H Kawabata; Y Kohsaka; M Okuma
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

6.  Platelet dysfunction as the presenting feature of atypical myelodysplastic syndrome with monosomy 7, normal blood counts and no bleeding tendency.

Authors:  D Marisavljević; P Antunović; P Miljić; M Pantić
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

7.  Initial transforming event in myelodysplastic syndromes may be viral: case for cytomegalovirus.

Authors:  A Raza
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.